Acacia Pharma Group plc Publication Of Annual Report 2020
March 30 2021 - 12:00AM
UK Regulatory
TIDMACPH
This announcement contains inside information for the purposes of
Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Acacia Pharma Group plc Publishes its Annual Report and Financial
Statements for the Year ended 31 December 2020
Cambridge, UK and Indianapolis, US -- 30 March 2021, 07:00 CEST: Acacia
Pharma Group plc ("Acacia Pharma", the "Group" or the "Company")
(EURONEXT: ACPH), a hospital pharmaceutical company focused on the
development and commercialization of new products aimed at improving the
care of patients undergoing significant treatments such as surgery,
other invasive procedures or cancer chemotherapy, announces the
publication of its Annual Report and Financial Statements for the Year
ended 31 December 2020.
The Annual Report is attached here and also available on
www.acaciapharma.com in the Investors/Financial Reports and
Presentations section.
Contacts
Acacia Pharma Group plc International Media
Mike Bolinder, CEO Mark Swallow, Frazer Hall, David
Gary Gemignani, CFO Dible
+44 1223 919760 / +1 317 505 1280 Citigate Dewe Rogerson
IR@acaciapharma.com +44 20 7638 9571
acaciapharma@citigatedewerogerson.com
US Investors Media in Belgium and the Netherlands
LifeSci Advisors Chris Van Raemdonck
Irina Koffler +32 499 58 55 31
+1 917-734-7387 chrisvanraemdonck@telenet.be
ikoffler@lifesciadvisors.com
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the
development and commercialization of new products aimed at improving the
care of patients undergoing significant treatments such as surgery,
other invasive procedures, or cancer chemotherapy. The Company has
identified important and commercially attractive unmet needs in these
areas that its product portfolio aims to address.
Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is
available in the US for the management of postoperative nausea &
vomiting (PONV).
BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV
benzodiazepine sedative is approved and launched in the US for use
during invasive medical procedures in adults lasting 30 minutes or less,
such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion
UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine
antagonist for chemotherapy induced nausea & vomiting (CINV) has
successfully completed one proof-of-concept and one Phase 2 dose-ranging
study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D
operations are centred in Cambridge, UK. The Company is listed on the
Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker
symbol ACPH.
Acacia Pharma Group plc
The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United
Kingdom
Company number 9759376
www.acaciapharma.com
Attachment
-- Acacia Pharma Group plc Annual Report and Financial Statements for the
Year ended 31 December 2020
https://ml-eu.globenewswire.com/Resource/Download/4ad20766-3e4a-441a-af09-3bdbe15a439e
(END) Dow Jones Newswires
March 30, 2021 01:00 ET (05:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about Acacia Pharma Group Plc (London Stock Exchange): 0 recent articles
More Acacia Pharma Group Plc News Articles